SFPQ Promotes Lung Cancer Malignancy via Regulation of CD44 v6 Expression

Libang Yang; Jianbo Yang; Jianbo Yang; Blake Jacobson; Adam Gilbertsen; Karen Smith; LeeAnn Higgins; Candace Guerrero; Hong Xia; Craig A. Henke; Jizhen Lin; Jizhen Lin

doi:10.3389/fonc.2022.862250

Frontiers in Oncology (May 2022)

SFPQ Promotes Lung Cancer Malignancy via Regulation of CD44 v6 Expression

Libang Yang,
Jianbo Yang,
Jianbo Yang,
Blake Jacobson,
Adam Gilbertsen,
Karen Smith,
LeeAnn Higgins,
Candace Guerrero,
Hong Xia,
Craig A. Henke,
Jizhen Lin,
Jizhen Lin

Affiliations

Libang Yang: Department of Medicine, University of Minnesota, Minneapolis, MN, United States
Jianbo Yang: Department of Laboratory Medicine and Pathology, School of Medicine, University of Minneapolis, Minneapolis, MN, United States
Jianbo Yang: The Cancer Center, Fujian Medical University Union Hospital, Fuzhou, China
Blake Jacobson: Hematology, Oncology and Transplantation, School of Medicine, University of Minnesota, Minneapolis, MN, United States
Adam Gilbertsen: Department of Medicine, University of Minnesota, Minneapolis, MN, United States
Karen Smith: Department of Medicine, University of Minnesota, Minneapolis, MN, United States
LeeAnn Higgins: Center for Mass Spectrometry and Proteomics, University of Minnesota, St. Paul, MN, United States
Candace Guerrero: Center for Mass Spectrometry and Proteomics, University of Minnesota, St. Paul, MN, United States
Hong Xia: Department of Medicine, University of Minnesota, Minneapolis, MN, United States
Craig A. Henke: Department of Medicine, University of Minnesota, Minneapolis, MN, United States
Jizhen Lin: The Cancer Center, Fujian Medical University Union Hospital, Fuzhou, China
Jizhen Lin: The Immunotherapy Research Laboratory, Department of Otolaryngology, Cancer Center, University of Minnesota, Minneapolis, MN, United States

DOI: https://doi.org/10.3389/fonc.2022.862250
Journal volume & issue: Vol. 12

Abstract

Read online

Mesenchymal stem cells (MSCs) contribute to tumor pathogenesis and elicit antitumor immune responses in tumor microenvironments. Nuclear proteins might be the main players in these processes. In the current study, combining spatial proteomics with ingenuity pathway analysis (IPA) in lung non-small cell (NSC) cancer MSCs, we identify a key nuclear protein regulator, SFPQ (Splicing Factor Proline and Glutamine Rich), which is overexpressed in lung cancer MSCs and functions to promote MSCs proliferation, chemical resistance, and invasion. Mechanistically, the knockdown of SFPQ reduces CD44v6 expression to inhibit lung cancer MSCs stemness, proliferation in vitro, and metastasis in vivo. The data indicates that SFPQ may be a potential therapeutic target for limiting growth, chemotherapy resistance, and metastasis of lung cancer.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords